VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.6 EUR | +1.63% |
|
+3.64% | -2.73% |
| 03-20 | Vetoquinol SA Proposes Dividend | CI |
| 03-20 | Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
99.6
EUR
Average target price
108.4
EUR
Spread / Average Target
+8.85%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.73% | 1.26B | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -2.92% | 3.12B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -14.67% | 1.12B | |
| -5.37% | 990M | |
| -24.06% | 805M |
- Stock Market
- Equities
- VETO Stock
- News Vetoquinol SA
- Vetoquinol : Buys Canadian Rights to Profender Products for Cats
